SCHEMBL3888747

SCHEMBL3888747

CCCOC(=O)c1cc2c(o1)c(NC(=O)c1ccc(F)cc1)nn2C(=O)c1ccc(F)cc1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.43
NPSR1 Q6W5P4 1/20 0.43
GPR35 Q9HC97 1/20 0.41
ELANE P08246 4/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
RAB9A P51151 1/20 0.41
ADCY1 Q08828 1/20 0.39
P2RY14 Q15391 1/20 0.39
CXCR1 P25024 1/20 0.38
CXCR2 P25025 1/20 0.38
ALDH1A1 P00352 2/20 0.37
MAPK1 P28482 1/20 0.37
MAPT P10636 2/20 0.37
HPGD P15428 1/20 0.37
TP53 P04637 1/20 0.37
KDM4E B2RXH2 1/20 0.37
ADORA3 P0DMS8 1/20 0.37
ADORA2A P29274 1/20 0.37
ADORA1 P30542 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4091779 0.93 LMNA (0.44) LMNANPSR1GPR35ELANESMN1; SMN2
SCHEMBL3880434 0.86 LRRK2 (0.47) LMNASMN1; SMN2RAB9AALDH1A1MAPK1
SCHEMBL3880690 0.85 MAPT (0.46) RAB9AMAPTHPGD
SCHEMBL4088637 0.83 ALDH1A1 (0.43) LMNANPSR1GPR35ELANESMN1; SMN2
SCHEMBL4078418 0.83 HTT (0.43) LMNAELANESMN1; SMN2RAB9AALDH1A1
SCHEMBL4078227 0.83 PAX8 (0.45) LMNAGPR35ELANESMN1; SMN2ALDH1A1
SCHEMBL4083509 0.82 GPR35 (0.49) LMNANPSR1GPR35ELANESMN1; SMN2
SCHEMBL4083134 0.82 GPR35 (0.42) GPR35ELANESMN1; SMN2RAB9AALDH1A1
SCHEMBL4078733 0.81 ALDH1A1 (0.44) LMNAGPR35ELANESMN1; SMN2P2RY14
SCHEMBL4088619 0.80 GPR35 (0.42) GPR35ELANERAB9AALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7485661-B2 Heterobicyclic pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2009-02-03 US disclosed
EP-1534716-B1 HETEROBICYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PFIZER ITALIA SRL (IT) 2008-04-23 EP disclosed
US-20060160874-A1 Heterobicyclic pyrazole derivatives as kinase inhibitors PHARMACIA ITALIA S.P.A. (IT) 2006-07-20 US disclosed
EP-1534716-A1 HETEROBICYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2005-06-01 EP disclosed
WO-2004007504-A1 HETEROBICYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2004-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160874-A1 Heterobicyclic pyrazole derivatives as kinase inhibitors MAP2K2, MAP3K15, MAP3K5 LMNA 3710/4885NPSR1 4651/4885GPR35 1563/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.